COVID-19 in the Critically Ill: Too Risky for High-Dose Anticoagulation?
Chest
.
2021 Aug;160(2):e249.
doi: 10.1016/j.chest.2021.03.028.
Authors
Juan José Paez Vargas
1
,
Anxela Vidal González
2
,
César Pérez-Calvo
2
,
Javier Flandes
3
Affiliations
1
Intensive Care Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. Electronic address: jjpaezv@icloud.com.
2
Intensive Care Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
3
Interventional Pulmonology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
PMID:
34366058
PMCID:
PMC8339404
DOI:
10.1016/j.chest.2021.03.028
No abstract available
Publication types
Letter
Comment
MeSH terms
Anticoagulants / adverse effects
Blood Coagulation
COVID-19*
Critical Illness*
Humans
SARS-CoV-2
Substances
Anticoagulants